Clinical Trials Browser

Phase 2 × INDUSTRY × Rubinstein-Taybi Syndrome × Clear all

NCT02236195 2017-09-01

Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes

Phase 2 Completed

Carcinoma, Transitional Cell, Rubinstein-Taybi Syndrome